Avvio Medical Establishes New Ureteral Stone Treatment Vertical at AUA 2026 Annual Meeting
Showcase Presentation at AUA 2026 Innovation Nexus Ignites Excitement Around a New Era in Stone Management
Avvio Medical, a clinical-stage medical device company developing Microbubble SonoLithotripsy for the treatment of ureteral stones, reports today on its successful conference at the 2026 American Urological Association (AUA) Annual Meeting, held May 15-18 in Washington, DC. The companyadvanced its mission of making ureteral obstruction therapy local, immediate, safe, and free of routine use of stents and anesthesia.
A Showcase Moment at the AUA Innovation Nexus
Avvio Medical was selected as a showcase presenter at the AUA Innovation Nexus on Thursday, May 14, a curated platform reserved for the most compelling companies advancing the future of urology. CEO Paul Molloy took the stage to introduce Microbubble SonoLithotripsy to an audience of urologists, industry leaders, and investors. The presentation generated significant investor and strategic interest, with attendees recognizing the technology as a long-overdue answer to a persistent challenge: the gap between diagnosis and treatment in a system strained by OR scheduling delays and growing wait times.
